Synthesis and Anti-HIV Activity of New Metabolically Stable Alkenyldiarylmethane Non-Nucleoside Reverse Transcriptase Inhibitors Incorporating N-Methoxy Imidoyl Halide and 1,2,4-Oxadiazole Systems
摘要:
The alkenyldiarylmethanes (ADAMs) are a unique class of non-nucleoside reverse transcriptase inhibitors (NNRTIs) that are capable of inhibiting HIV-1 reverse transcriptase (RT) through an allosteric mechanism. However, the potential usefulness of the ADAMs is limited by the presence of metabolically labile methyl ester moieties that are hydrolyzed by nonspecific esterases present in blood plasma, resulting in the formation of the inactive carboxylic acid metabolites. Therefore, to discover metabolically stable ADAMs, the design and synthesis of a new class of ADAMs with N-methoxy imidoyl halide and 1,2,4-oxadiazole systems were attempted. The resulting new ADAM 6 displayed enhanced metabolic stability in rat plasma (t(1/2) = 61 h) along with the ability to inhibit HIV-1 reverse transcriptase and the cytopathic effect of HIV-1(RF) and HIV-1(IIIB) at submicromolar concentrations.
[EN] ALKENYLDIARYLMETHANES HAVING NITROGEN-CONTAINING CARBOXYLIC ACID DERIVATIVES<br/>[FR] ALCÉNYLDIARYLMÉTHANES PRÉSENTANT DES DÉRIVÉS D'ACIDE CARBOXYLIQUE CONTENANT DE L'AZOTE
申请人:CUSHMAN MARK S
公开号:WO2008119028A1
公开(公告)日:2008-10-02
[EN] Alkenydiarylmethane compounds are described. Such compounds are a class of non-nucleoside inhibitors of HIV-I reverse transcriptase, which may also be used as part of a combination therapy to treat HIV infection. Compounds described herein exhibit antiviral potency. In addition, compounds described herein exhibit metabolic stability. Also described herein are processes for preparing alkenydiarylmethane compounds. [FR] La présente invention concerne des composés alcényldiarylméthanes. Ces composés constituent une catégorie d'inhibiteurs non-nucléosides de la transcriptase inverse du VIH-I, qui peuvent également être utilisés dans le cadre d'une thérapie combinatoire visant à traiter une infection par le VIH. Les composés décrits ici présentent une activité antivirale. Ces composés possèdent en outre une stabilité métabolique. La présente invention concerne également des procédés de préparation de composés alcényldiarylméthanes.